Rachel Bennett1, Nick Maskell. 1. Department of Respiratory Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Abstract
PURPOSE OF REVIEW: Although malignant pleural effusions are a common medical problem, research into their optimal management remains sparse. The aim of this review is to summarise recent developments in this area. RECENT FINDINGS: Talc remains the most efficacious pleurodesis agent. However, concerns remain about its side effect profile, with a number of cases of acute respiratory distress syndrome documented in the literature. A recent trial showed that using calibrated talc particles reduced the risk of morbidity from this procedure. Work on novel pleurodesis agents, such as transforming growth factor-beta, appears to induce pleurodesis in animal models without any unwanted side effects. This is a promising development and human trials are awaited. With regard to mesothelioma, recent chemotherapy trials with pemetrexed/cisplatin and raltitrexed/cisplatin are encouraging and appear, for the first time, to offer a small but real survival advantage. SUMMARY: In the authors' opinion, the major developments in the management of malignant effusions during the past year are the development of safer pleurodesis agents and the promise of better combination chemotherapy agents for the treatment of mesothelioma.
PURPOSE OF REVIEW: Although malignant pleural effusions are a common medical problem, research into their optimal management remains sparse. The aim of this review is to summarise recent developments in this area. RECENT FINDINGS: Talc remains the most efficacious pleurodesis agent. However, concerns remain about its side effect profile, with a number of cases of acute respiratory distress syndrome documented in the literature. A recent trial showed that using calibrated talc particles reduced the risk of morbidity from this procedure. Work on novel pleurodesis agents, such as transforming growth factor-beta, appears to induce pleurodesis in animal models without any unwanted side effects. This is a promising development and human trials are awaited. With regard to mesothelioma, recent chemotherapy trials with pemetrexed/cisplatin and raltitrexed/cisplatin are encouraging and appear, for the first time, to offer a small but real survival advantage. SUMMARY: In the authors' opinion, the major developments in the management of malignant effusions during the past year are the development of safer pleurodesis agents and the promise of better combination chemotherapy agents for the treatment of mesothelioma.
Authors: Kelly A Kreuter; Naglaa El-Abbadi; Alia Shbeeb; Lillian Tseng; Sari Brenner Mahon; Navneet Narula; Tanya Burney; Henri Colt; Matthew Brenner Journal: Comp Med Date: 2008-06 Impact factor: 0.982
Authors: Wu Feize; Liu Meng; Lou Yanni; Li Yuan; Jia Liqun; Li Tong; Yang Guowang; Cui Huijuan; Wan Donggui; Cheng Zhiqiang; Zheng Lei Journal: Integr Cancer Ther Date: 2016-07-18 Impact factor: 3.279
Authors: Stephanie Weibel; Elisabeth Hofmann; Thomas Christian Basse-Luesebrink; Ulrike Donat; Carolin Seubert; Marion Adelfinger; Prisca Gnamlin; Christina Kober; Alexa Frentzen; Ivaylo Gentschev; Peter Michael Jakob; Aladar A Szalay Journal: J Transl Med Date: 2013-05-01 Impact factor: 5.531
Authors: Ihsan Inan; Sandra De Sousa; Patrick O Myers; Brigitte Bouclier; Pierre-Yves Dietrich; Monica E Hagen; Philippe Morel Journal: World J Surg Oncol Date: 2008-08-18 Impact factor: 2.754